These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31218976)

  • 1. Delayed Patient Access to Innovative Medical Technologies in South Korea: A Lead-Time Analysis of Reimbursement Coverage Determinations.
    Lee SS; Myung JE; Strachan L
    Int J Technol Assess Health Care; 2019 Jan; 35(3):229-236. PubMed ID: 31218976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
    Lee SS; Salole E
    Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement Coverage Decision Making for Digital Health Technologies in South Korea: Does It Fit the Value Framework Used in Traditional Medical Technologies?
    Myung JE; Strachan L; Shin J; Yim J; Lee SS
    Value Health Reg Issues; 2023 Jul; 36():27-33. PubMed ID: 37019064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 5. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of expanding health insurance coverage for anti-cancer drugs on cancer survival in Korea.
    Cho DY; Park J; Kim DS
    Cancer Med; 2021 Jul; 10(13):4555-4563. PubMed ID: 34145980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 1: issues in medical device assessment.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Sep; 3(9):694-702. PubMed ID: 17412151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the Impact of the Current Reimbursement Regulation on Patient Access to Innovative Medical Devices in Taiwan: Insights From 8 Years' Reimbursement Data.
    Peng JY; Lee SS; Lin CR; Lee H; Chen YC
    Value Health Reg Issues; 2024 Jul; 42():100978. PubMed ID: 38350187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare is scrutinizing evidence more tightly for national coverage determinations.
    Chambers JD; Chenoweth M; Cangelosi MJ; Pyo J; Cohen JT; Neumann PJ
    Health Aff (Millwood); 2015 Feb; 34(2):253-60. PubMed ID: 25646105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative Medical Technology, Health Technology Assessment, and Health Policy: The Case of Remote Patient Monitoring of Cardiac Implantable Electronic Devices in South Korea.
    Lee SS; Salole E
    Telemed J E Health; 2017 Jan; 23(1):25-29. PubMed ID: 27285669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family income and the impact of a children's health insurance program on reported need for health services and unmet health need.
    Feinberg E; Swartz K; Zaslavsky A; Gardner J; Walker DK
    Pediatrics; 2002 Feb; 109(2):E29. PubMed ID: 11826239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving provider payment models and patient access to innovative medical technology.
    Long G; Mortimer R; Sanzenbacher G
    J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on current status of health technology reassessment: insights for South Korea.
    Seo HJ; Park JJ; Lee SH
    Health Res Policy Syst; 2016 Nov; 14(1):82. PubMed ID: 27835964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
    Cho E; Yoo SL; Kang Y; Lee JH
    Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.